Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content

28 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/28/3246892/0/en/Cogent-Biosciences-Highlights-Additional-Data-with-Six-Bezuclastinib-Posters-from-SUMMIT-Trial-at-2026-AAAAI-Annual-Meeting.html

17 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/17/3239198/0/en/Cogent-Biosciences-Reports-Recent-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

10 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/10/3235231/0/en/Cogent-Biosciences-Announces-Multiple-SUMMIT-Posters-at-the-2026-AAAAI-Annual-Meeting.html

26 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/26/3225587/0/en/Cogent-Biosciences-Announces-Breakthrough-Therapy-Designation-for-Bezuclastinib-in-Combination-with-Sunitinib-for-Patients-with-Gastrointestinal-Stromal-Tumors-GIST.html

20 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html

20 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html
ABOUT THIS PAGE